Christine Tarby
About Christine Tarby
Christine Tarby is the Associate Director of Enterprise Governance at Bristol-Myers Squibb, with over 20 years of experience in the pharmaceutical industry.
Title
Christine Tarby is the Associate Director, Enterprise Governance at Bristol-Myers Squibb. In this role, she oversees various governance-related initiatives to ensure they align with the company's strategic goals and regulatory requirements.
Company
Christine Tarby currently works at Bristol-Myers Squibb, where she took on the role of Associate Director, Enterprise Governance in March 2020. Bristol-Myers Squibb is a globally recognized pharmaceutical company known for its innovative treatments and commitment to addressing serious diseases.
Background
Christine Tarby has an extensive background in the pharmaceutical industry, accumulating over 20 years of experience. She has held various leadership roles at prominent companies, including serving as Principal Scientist at DuPont Pharmaceuticals from 1999 to 2001 in Wilmington, Delaware, and as Principal Scientist at CombiChem from 1995 to 1999 in La Jolla, California. Her career has been marked by significant contributions in scientific research and enterprise governance.
Education and Expertise
Christine Tarby holds a Doctor of Philosophy from Scripps Research, completed between 1993 and 1996. She also earned a Bachelor of Arts from Drew University, where she studied from 1985 to 1989. Christine’s strong academic background has provided her with a solid foundation, supporting her extensive experience in both scientific and governance roles within the pharmaceutical industry.
Achievements
Christine Tarby has successfully transitioned from a career focused on scientific research to one involved in enterprise governance. Her tenure at companies like DuPont Pharmaceuticals and CombiChem attests to her capability in leading scientific initiatives, while her current role at Bristol-Myers Squibb highlights her expertise in governance. Her career reflects a commitment to advancing the pharmaceutical industry through both innovative research and robust governance practices.